最新予防接種戦略<br>Novel Vaccination Strategies

個数:
  • ポイントキャンペーン

最新予防接種戦略
Novel Vaccination Strategies

  • ウェブストア価格 ¥43,178(本体¥39,253)
  • Wiley-VCH(2004発売)
  • 外貨定価 EUR 165.00
  • クリスマスポイント2倍キャンペーン(~12/25)
  • ポイント 784pt
  • 在庫がございません。海外の書籍取次会社を通じて出版社等からお取り寄せいたします。
    通常6~9週間ほどで発送の見込みですが、商品によってはさらに時間がかかることもございます。
    重要ご説明事項
    1. 納期遅延や、ご入手不能となる場合がございます。
    2. 複数冊ご注文の場合は、ご注文数量が揃ってからまとめて発送いたします。
    3. 美品のご指定は承りかねます。

    ●3Dセキュア導入とクレジットカードによるお支払いについて
  • ≪洋書のご注文について≫ 「海外取次在庫あり」「国内在庫僅少」および「国内仕入れ先からお取り寄せいたします」表示の商品でもクリスマス前(12/20~12/25)および年末年始までにお届けできないことがございます。あらかじめご了承ください。

  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Hardcover:ハードカバー版/ページ数 670 p.
  • 商品コード 9783527305230

基本説明

Offers an interdisciplinary overview on research and future strategies for rational vaccine design based on recent developments in molecular biology and immunology. It covers new aspects of the immunological interplay between prokaryotic and eukaryotic systems as well as achievements in the development of novel vaccine candidates.

Full Description


The protection mode of most available vaccines is based on antibody responses. Since efficient immune responses to many pathogens rely on activating all arms of the immune system, traditional vaccine development does not provide efficient protection against many diseases. Novel vaccination strategies need to allow presentation of antigens that activate the full array of the immune response in the right composition and should prevent pathogen entry by mobilizing the mucosal immune response. New technological advances optimize the immunogenicity of 'live' and sub--unit vaccines. This book offers an interdisciplinary overview on research and future strategies for rational vaccine design based on recent developments in molecular biology and immunology. It covers new aspects of the immunological interplay between prokaryotic and eukaryotic systems as well as achievements in the development of novel vaccine candidates. Chapters on edible vaccines, on vaccines against bioterror agents and on economical and safety aspects of novel vaccine development round off this title.

Contents

Colour Plates.PART I.1. Challenges for the Vaccine Developer, including Correlates of Protection (G. Nossal). PART II: VACCINATION AND IMMUNE RESPONSE.2. Shaping Adaptive Immunity against Pathogens: The Contribution of Innate Immune Responses (S. Ehlers & S. Bulfone-Paus).3. Adjuvant-induced Th2- and Th1 -dominated Immune Responses in Vaccination (J. Brewer & K. Pollock).4. Memory (A. Ploss & E. Pamer).5. T-Cell based Vaccines (K. Huster, et al.). PART III: ADJUVANTS.6. Microbial Adjuvants (K. Heeg, et al.). 7. Host-derived Adjuvants (N. Hilf, et al.). 8. Microparticles as Vaccine Adjuvants and Delivery Systems (D. O'Hagan & M. Singh).9. Liposomes and ISCOMs (G. Kersten, et al.). 10. Virosomal Technology and Mucosal Adjuvants (J. Viret, et al.). PART IV: CLASSICAL AND NOVEL VACCINATION STRATEGIES: A COMPARISON.11. Classical Bacterial Vaccines (T. Ebensen, et al.). 12. Subunit Vaccines and Toxoids (M. Lattanzi, et al.). 13. Engineering Virus Vectors for Subunit Vaccines (J. Nkolola & T. Hanke).14. Update on Antiviral DNA Vaccine Research (2000-2003) (D. Franke, et al.).15. Live Recombinant Bacterial Vaccines (S. Clare & G. Dougan).16. Mucosal Vaccination (W. Olszewska & P. Openshaw).17. Passive Vaccination and Antidotes: A Novel Strategy for Generation of Wide-spectrum Protective Antibodies (A. Cassone & L. Polonelli).18. Plant-based Oral Vaccines (K. Wang, et al.). 19. Virus-like Particles: Combining Innate and Adaptive Immunity for Effective Vaccination (M. Bachmann & G. Jennings). PART V: VACCINES FOR SPECIFIC TARGETS.20. Helicobacter Pylori (P. Ruggiero, et al.). 21. Novel Vaccination Strategies against Tuberculosis (S. Kaufmann).22. Rationale for Malaria Vaccine Development (A. Saul, et al.).23. Vaccine for Specific Targets: HIV (R. Kay, et al.). 24. Vaccines against Bioterror Agents (K. Elkins, et al.). PART VI: VACCINES IN THE REAL WORLD: SAFETY, COST EFFICIENCY AND IMPACT OF VACCINATION.25. Imperfect Vaccines and the Evolution of Pathogen Virulence (P. Ewald).26. Cost-Effectiveness of Vaccinations (T. Szucs).27. Immunological Safety of Vaccines: Facts, Hypothesis and Allegations (M. Goldman & P. Lambert). Index.

最近チェックした商品